We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-7%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
-$528M
Cap. Flow
-$782M
Cap. Flow %
-27.48%
Top 10 Hldgs %
40.1%
Holding
81
New
10
Increased
17
Reduced
14
Closed
17
Avg Time Held
4.2 quarters
Top 10 Avg Time Held
2.6 quarters
Top 20 Avg Time Held
3 quarters

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$67.5M
2
ARGX icon
argenx
ARGX
+$50.5M
3
NUVL icon
Nuvalent
NUVL
+$46.9M
4
GKOS icon
Glaukos
GKOS
+$44.8M
5
BPMC icon
Blueprint Medicines
BPMC
+$42.9M

Top Sells

Rank Stock Value
1
GH icon
Guardant Health
GH
+$65.6M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$43.2M
3
FNA icon
Paragon 28, Inc.
FNA
+$39.6M
4
BNTX icon
BioNTech
BNTX
+$35.3M
5
RGEN icon
Repligen
RGEN
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 67.44%
2 Miscellaneous 32.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NBIX icon
1
Neurocrine Biosciences
NBIX
$13.8B
$132M 4.63%
1,191,925
+290,135
+32% +$36.8M
2023 Q1
8 quarters
LEGN icon
2
Legend Biotech
LEGN
$3.63B
$101M 3.55%
2,977,951
– –
2022 Q4
9 quarters
ARGX icon
3
argenx
ARGX
$52.2B
$95.2M 3.35%
160,849
+80,083
+99% +$50.5M
2023 Q4
5 quarters
XENE icon
4
Xenon Pharmaceuticals
XENE
$3.37B
$90.9M 3.2%
2,709,875
-204,089
-7% -$7.75M
2022 Q4
9 quarters
ALGN icon
5
Align Technology
ALGN
$10.1B
$84.3M 2.96%
530,530
+155,351
+41% +$30.5M
2022 Q4
9 quarters
CGON icon
6
CG Oncology
CGON
$5.58B
$80.4M 2.83%
3,283,317
– –
2024 Q1
4 quarters
KRYS icon
7
Krystal Biotech
KRYS
$9.73B
$72.3M 2.54%
400,744
+200,244
+100% +$33.7M
2022 Q4
9 quarters
TMO icon
8
Thermo Fisher Scientific
TMO
$250B
$63.6M 2.23%
127,733
+37,979
+42% +$20.6M
2024 Q4
1 quarter
DHR icon
9
Danaher
DHR
$159B
$63.4M 2.23%
+309,339
New +$67.5M
2025 Q1
0 quarters
GKOS icon
10
Glaukos
GKOS
$9.83B
$61.5M 2.16%
624,435
+335,559
+116% +$44.8M
2022 Q4
9 quarters
NUVL icon
11
DELISTED
Nuvalent
NUVL
$59.6M 2.1%
840,945
+599,710
+249% +$46.9M
2024 Q4
1 quarter
IRTC icon
12
iRhythm Holdings
IRTC
$3.48B
$58.2M 2.05%
556,391
-149,000
-21% -$15.8M
2022 Q4
9 quarters
APGE icon
13
DELISTED
Apogee Therapeutics
APGE
$57.5M 2.02%
1,540,362
– –
2023 Q3
6 quarters
TMDX icon
14
Transmedics
TMDX
$2.68B
$57.5M 2.02%
854,884
-67,216
-7% -$4.62M
2024 Q4
1 quarter
GH icon
15
Guardant Health
GH
$22.3B
$56.5M 1.99%
1,327,327
-1,520,604
-53% -$65.6M
2023 Q2
7 quarters
EWTX icon
16
Edgewise Therapeutics
EWTX
$3.95B
$54.1M 1.9%
2,458,808
+126,612
+5% +$3.32M
2024 Q3
2 quarters
INSP icon
17
Inspire Medical Systems
INSP
$2B
$48.2M 1.69%
302,410
+9,000
+3% +$1.63M
2023 Q3
6 quarters
KNSA icon
18
Kiniksa Pharmaceuticals
KNSA
$6.19B
$43.6M 1.53%
1,962,909
-1,489,538
-43% -$30.7M
2024 Q1
4 quarters
ISRG icon
19
Intuitive Surgical
ISRG
$149B
$43.6M 1.53%
88,000
+12,700
+17% +$7.02M
2024 Q1
4 quarters
ATEC icon
20
Alphatec Holdings
ATEC
$1.64B
$43.2M 1.52%
4,259,429
+2,939
+0.1% +$31.5K
2024 Q2
3 quarters
SYRE icon
21
Spyre Therapeutics
SYRE
$7.63B
$41.6M 1.46%
2,578,404
– –
2023 Q4
5 quarters
BPMC icon
22
DELISTED
Blueprint Medicines
BPMC
$38.9M 1.37%
+439,968
New +$42.9M
2025 Q1
0 quarters
DYN icon
23
Dyne Therapeutics
DYN
$2.86B
$37.9M 1.33%
3,621,344
+2,940,162
+432% +$42.1M
2024 Q4
1 quarter
APLS icon
24
DELISTED
Apellis Pharmaceuticals
APLS
$36.1M 1.27%
1,652,334
-446,532
-21% -$12.3M
2024 Q2
3 quarters
ADPT icon
25
Adaptive Biotechnologies
ADPT
$4.14B
$35.7M 1.25%
+4,803,794
New +$36.9M
2025 Q1
0 quarters
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q1 2025 Portfolio in Review

As of Q1 2025, Braidwell held 81 positions worth $2.84B, down 16% from $3.37B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Braidwell withdrew a net $782M in Q1 2025, closing 17 positions and reducing 14 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $43.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Danaher worth $63.4M.

  • Braidwell's largest Q1 2025 buy was Danaher: 309,339 shares worth $63.4M.
  • Braidwell added most to argenx in Q1 2025, an estimated $50.5M increase.
  • Braidwell's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $65.6M.
  • Braidwell fully exited Avadel Pharmaceuticals in Q1 2025, selling an estimated $43.2M.
  • Braidwell's ten largest holdings make up 40% of its $2.84B portfolio in Q1 2025.
  • Braidwell opened 10 new positions and closed 17 in Q1 2025.
  • Braidwell's portfolio value fell 16% quarter-over-quarter to $2.84B.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.